_PRIVATE_LIMITED_403818.webp)
Pharmapoint (India) Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 18-12-2024
- Paid Up Capital ₹ 0.30 M
as on 18-12-2024
- Company Age 29 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 11.36 Cr
as on 18-12-2024
- Revenue 34.97%
(FY 2024)
- Profit 2.30%
(FY 2024)
- Ebitda -3.76%
(FY 2024)
- Net Worth 20.54%
(FY 2024)
- Total Assets -20.61%
(FY 2024)
About Pharmapoint (India)
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.30 M.
The company currently has active open charges totaling ₹11.36 Cr.
Manoj Lekhrajani and Anit Lekhrajani serve as directors at the Company.
- CIN/LLPIN
U24239MH1995PTC090194
- Company No.
090194
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Jul 1995
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Pharmapoint (India)?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manoj Lekhrajani  | Director | 04-Jul-1995 | Current |
| Anit Lekhrajani | Director | 04-Jul-1995 | Current |
Financial Performance and Corporate Structure Insights of Pharmapoint (India).
Pharmapoint (India) Private Limited, for the financial year ended 2024, experienced significant growth in revenue, with a 34.97% increase. The company also saw a slight improvement in profitability, with a 2.3% increase in profit. The company's net worth Soared by an impressive increase of 20.54%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pharmapoint (India)?
In 2024, Pharmapoint (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Absolute Distribution Solutions Private LimitedActive 13 years 5 daysManoj Lekhrajani and Anit Lekhrajani are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 25 Sep 2020 | ₹5.00 Cr | Open |
Hdfc Bank Limited Creation Date: 15 Mar 2018 | ₹6.36 Cr | Open |
How Many Employees Work at Pharmapoint (India)?
Pharmapoint (India) has a workforce of 32 employees as of Dec 18, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pharmapoint (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pharmapoint (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
